We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Reference sheet · Signaling · CPC catalog code SIGN-002
Composition figures above are derived arithmetically from the published sequence for the unmodified free peptide. Salt forms (commonly trifluoroacetate or acetate), amidation, and other modifications shift the observed mass — always reconcile against the current lot certificate of analysis.
Volumes for a 1 mg vial of Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain at common working concentrations. Add solvent slowly down the vial wall and swirl — do not vortex or shake.
Reference standards in the Signaling class are typically shipped as lyophilized powder and stored desiccated at −20 °C protected from light. Once reconstituted in bacteriostatic water or the assay-appropriate buffer, aliquot and store at −80 °C to minimize freeze–thaw cycles. Confirm handling requirements against your institutional biosafety and radiation protocols before use.
Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain sits within the Signaling research class (CPC reference SIGN-002). Signaling peptides mimic recognition motifs (phosphotyrosine motifs, PDZ ligands, kinase docking sites) or interfere with protein–protein interactions inside the cell, allowing focused perturbation of a single node in a pathway. Investigators typically incorporate Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain as a reference standard, tool ligand, or substrate in the assay contexts listed above. SPR, BLI, AlphaScreen, and pulldown / Western readouts.
Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain (CPC catalog code SIGN-002) is a synthetic cell-signaling research peptide in the signaling category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.
Published and internal research programs use Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain as a reference standard in signaling workflows — for example, protein–protein interaction (ppi) mapping and sh2, sh3, pdz, and 14-3-3 binding studies. Human clinical evidence is not established.
No. Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.
In a signaling workflow, Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. SPR, BLI, AlphaScreen, and pulldown / Western readouts.
Other reference standards in the same class — commonly cross-referenced during assay design and comparator selection.